KYMR — Kymera Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.87bn
- $2.41bn
- $47.07m
- 37
- 12
- 94
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.65 | ||
| Price to Tang. Book | 3.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 48.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -32.38% | ||
| Return on Equity | -32.17% | ||
| Operating Margin | -472.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34.03 | 72.83 | 46.83 | 78.59 | 47.07 | 65.7 | 67.99 | 74.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Directors
- Bruce Booth NEC (47)
- Nello Mainolfi PRE (42)
- Bruce Jacobs CFO (51)
- Richard Chesworth CSO (50)
- Elaine Caughey OTH
- Jared Gollob OTH (57)
- Jeffrey Albers IND (49)
- Pamela Esposito IND (47)
- Steven Hall IND (66)
- Joanna Horobin IND (66)
- Gorjan Hrustanovic IND (32)
- John Maraganore IND (58)
- Donald Nicholson IND
- Elena Ridloff IND (41)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 29th, 2015
- Public Since
- August 21st, 2020
- No. of Shareholders
- 18
- No. of Employees
- 208
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 65,119,568
- Address
- 500 North Beacon Street, 4Th Floor, WATERTOWN, 02472
- Web
- https://www.kymeratx.com/
- Phone
- +1 8572855314
- Contact
- Justine Koenigsberg
- Auditors
- Ernst & Young LLP
Upcoming Events for KYMR
Q3 2025 Kymera Therapeutics Inc Earnings Release
Similar to KYMR
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Kymera Therapeutics share price?
As of Today at 21:40 UTC, shares in Kymera Therapeutics are trading at $44.12. This share price information is delayed by 15 minutes.
How has the Kymera Therapeutics share price performed this year?
Shares in Kymera Therapeutics last closed at $44.12 and the price had moved by +46% over the past 365 days. In terms of relative price strength the Kymera Therapeutics share price has outperformed the S&P500 Index by +29.14% over the past year.
What are the analyst and broker recommendations for Kymera Therapeutics?
The overall consensus recommendation for Kymera Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kymera Therapeutics dividend yield?
Kymera Therapeutics does not currently pay a dividend.
Does Kymera Therapeutics pay a dividend?
Kymera Therapeutics does not currently pay a dividend.
When does Kymera Therapeutics next pay dividends?
Kymera Therapeutics does not currently pay a dividend.
How do I buy Kymera Therapeutics shares?
To buy shares in Kymera Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kymera Therapeutics?
As of the previous close price of $44.12, shares in Kymera Therapeutics had a market capitalisation of $2.87bn.
Where are Kymera Therapeutics shares listed?
Here are the trading details for Kymera Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KYMR
What kind of share is Kymera Therapeutics?
Based on an overall assessment of its quality, value and momentum Kymera Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kymera Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Kymera Therapeutics is $60.67. That is 37.51% above the last closing price of $44.12.
Analysts covering Kymera Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.52 for the next financial year.
Find out moreWhat is the trend in the Kymera Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kymera Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +5.26%.
As of the last closing price of $44.12, shares in Kymera Therapeutics were trading +11.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kymera Therapeutics PE Ratio?
The Kymera Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $44.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kymera Therapeutics?
Kymera Therapeutics' management team is headed by:
- Bruce Booth - NEC
- Nello Mainolfi - PRE
- Bruce Jacobs - CFO
- Richard Chesworth - CSO
- Elaine Caughey - OTH
- Jared Gollob - OTH
- Jeffrey Albers - IND
- Pamela Esposito - IND
- Steven Hall - IND
- Joanna Horobin - IND
- Gorjan Hrustanovic - IND
- John Maraganore - IND
- Donald Nicholson - IND
- Elena Ridloff - IND